Form 4: Ionis CEO Monia Reports Equity Transactions

Ionis Pharmaceuticals CEO Brett P. Monia reported the vesting of restricted stock units, a tax-related share sale, and new equity grants.

Summary

• Brett P. Monia, CEO and Director of Ionis Pharmaceuticals Inc. (IONS), reported multiple transactions involving the company's common stock and derivative securities.
• On January 15, 2026, Monia acquired 89,145 shares of common stock through the vesting and release of Restricted Stock Unit (RSU) awards.
• Following this acquisition, Monia directly owned 268,717 shares of common stock.
• On January 16, 2026, Monia sold 44,034 shares of common stock at a weighted average price of $74.82 per share (ranging from $74.57 to $75.07) to cover tax withholding obligations related to the RSU vesting.
• After the sale, Monia's direct beneficial ownership of common stock was 224,683 shares.
• On January 15, 2026, Monia was granted 113,880 Performance Restricted Stock Units (PRSUs) under the 2011 Equity Incentive Plan, representing the maximum number that may be earned (200% of target).
• These PRSUs may vest at the end of a three-year performance period, based on the company's relative total shareholder return compared to a peer group.
• Also on January 15, 2026, Monia was granted 42,705 Restricted Stock Units (RSUs) under the same plan, which will vest in four equal annual installments.
• Each RSU represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.

Sentiment

Score: 5

Explanation: The filing is a routine report of insider transactions, including equity grants and a tax-related sale, which are neutral in sentiment. It reflects standard executive compensation practices without indicating any significant positive or negative operational or financial news.

Positives

• The grant of 113,880 Performance Restricted Stock Units (PRSUs) and 42,705 Restricted Stock Units (RSUs) indicates continued long-term incentive alignment for the CEO with shareholder interests.
• The PRSUs are tied to the company's relative total shareholder return, incentivizing strong performance against peers.

Negatives

• A sale of 44,034 shares of common stock, although for tax withholding purposes, reduces the CEO's direct equity ownership.

Risks

• The vesting of the 113,880 Performance Restricted Stock Units (PRSUs) is not guaranteed and depends entirely on Ionis Pharmaceuticals' relative total shareholder return compared to a peer group over a three-year performance period, with actual vesting potentially ranging from zero to the maximum stated amount.

Future Outlook

The Performance Restricted Stock Units (PRSUs) granted may vest at the end of a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group. The newly granted Restricted Stock Units (RSUs) will vest in four equal annual installments.

Industry Context

This filing represents routine executive compensation and insider transaction reporting common in the biotechnology and pharmaceutical industry. Equity grants like PRSUs and RSUs are standard mechanisms to align executive incentives with long-term company performance and shareholder value in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The use of Performance Restricted Stock Units (PRSUs) tied to relative total shareholder return (TSR) is a common practice in the biopharmaceutical industry for executive compensation, aligning incentives with competitive performance. Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar performance-based equity awards.
• The vesting schedule for Restricted Stock Units (RSUs) in four equal annual installments is a standard approach to retain executives and provide long-term incentives, comparable to practices at peer companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals.
• The automatic sale of shares to cover tax withholding obligations upon RSU vesting is a routine and expected event for executives receiving equity compensation across all industries, including biotech.

Stakeholder Impact

• Shareholders: The grant of performance-based equity awards aligns the CEO's incentives with shareholder returns, potentially benefiting long-term value. The tax-related sale is a routine event with minimal direct impact.
• Employees: The equity incentive plan provides a framework for executive compensation, which can influence overall compensation philosophy within the company.

Next Steps

• The Performance Restricted Stock Units (PRSUs) will be evaluated for vesting at the end of their three-year performance period, based on relative total shareholder return.
• The newly granted Restricted Stock Units (RSUs) will continue to vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Brett P. Monia, SEC Form 4, Insider Trading, Restricted Stock Units, Performance Restricted Stock Units, Equity Incentive Plan, Executive Compensation, Stock Sale, Tax Withholding